Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with
KRAS mutation
anti-VEGF
colorectal cancer
epigenetics
predictive biomarker
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
03
2020
accepted:
04
05
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
epublish
Résumé
Despite effective treatments, metastatic colorectal cancer (mCRC) prognosis is still poor, mostly in A randomized, open-label, two-arm, multicenter phase-II study will be performed to explore whether the addition of VPA to first line bevacizumab/oxaliplatin/fluoropyrimidine regimens (mFOLFOX-6/mOXXEL) might improve progression-free survival (PFS) in The "Revolution" study aims to improve the treatment efficacy of EudraCT: 2018-001414-15; ClinicalTrials.gov identifier: NCT04310176.
Sections du résumé
BACKGROUND
BACKGROUND
Despite effective treatments, metastatic colorectal cancer (mCRC) prognosis is still poor, mostly in
METHODS/DESIGN
METHODS
A randomized, open-label, two-arm, multicenter phase-II study will be performed to explore whether the addition of VPA to first line bevacizumab/oxaliplatin/fluoropyrimidine regimens (mFOLFOX-6/mOXXEL) might improve progression-free survival (PFS) in
DISCUSSION
CONCLUSIONS
The "Revolution" study aims to improve the treatment efficacy of
TRIAL REGISTRATION
BACKGROUND
EudraCT: 2018-001414-15; ClinicalTrials.gov identifier: NCT04310176.
Identifiants
pubmed: 32849914
doi: 10.1177/1758835920929589
pii: 10.1177_1758835920929589
pmc: PMC7425244
doi:
Banques de données
ClinicalTrials.gov
['NCT04310176']
Types de publication
Journal Article
Langues
eng
Pagination
1758835920929589Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Target Oncol. 2016 Feb;11(1):107-14
pubmed: 26826025
Oncologist. 2018 Feb;23(2):157-e21
pubmed: 29133513
J Clin Oncol. 2007 May 20;25(15):1979-85
pubmed: 17513804
J Cell Physiol. 2011 Sep;226(9):2378-90
pubmed: 21660961
Immunity. 2016 Mar 15;44(3):698-711
pubmed: 26982367
Oncotarget. 2016 Feb 16;7(7):7715-31
pubmed: 26735339
Cancer Biol Ther. 2009 May;8(9):782-91
pubmed: 19270508
Leuk Res Treatment. 2014;2014:143479
pubmed: 24527217
Mol Cancer. 2005 Jul 07;4(1):22
pubmed: 16001982
Trends Immunol. 2016 Jul;37(7):462-476
pubmed: 27216414
Pharmacol Ther. 2016 Apr;160:145-58
pubmed: 26899500
Cancer Chemother Pharmacol. 2012 Aug;70(2):251-8
pubmed: 22744359
J Neurooncol. 2018 Apr;137(2):349-356
pubmed: 29264836
Cancer Treat Rev. 2008 May;34(3):206-22
pubmed: 18226465
Anticancer Res. 2016 Oct;36(10):5079-5086
pubmed: 27798867
Br J Pharmacol. 2007 May;151(1):63-72
pubmed: 17351657
Breast Cancer Res Treat. 2012 Apr;132(3):1063-72
pubmed: 22200869
BMC Cancer. 2016 Feb 08;16:69
pubmed: 26857924
BMC Urol. 2012 Aug 16;12:21
pubmed: 22898175
PLoS One. 2015 Jul 30;10(7):e0134594
pubmed: 26226632
Nat Struct Mol Biol. 2010 Sep;17(9):1144-51
pubmed: 20802485
Int J Urol. 2007 Sep;14(9):838-45
pubmed: 17760752
Oncologist. 2007 Oct;12(10):1247-52
pubmed: 17962618
Clin Cancer Res. 2011 Feb 1;17(3):589-97
pubmed: 21115653
Cancer Lett. 2009 Aug 8;280(2):145-53
pubmed: 19111391
J Biomed Biotechnol. 2010;2010:
pubmed: 20798865
Nat Med. 2015 Jul;21(7):795-801
pubmed: 26030179
Cytometry A. 2016 Mar;89(3):259-70
pubmed: 26305912
J Clin Oncol. 2017 Apr 10;35(11):1231-1239
pubmed: 28221861
Epigenomics. 2011 Aug;3(4):451-70
pubmed: 22126205
Br J Cancer. 2007 Jul 16;97(2):177-82
pubmed: 17579623
Neuro Oncol. 2015 Jun;17(6):862-7
pubmed: 25572329
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
BMC Cancer. 2014 Nov 24;14:875
pubmed: 25421252
Clin Cancer Res. 2009 Apr 1;15(7):2488-96
pubmed: 19318486
Recent Pat Anticancer Drug Discov. 2007 Jun;2(2):119-34
pubmed: 18221057
Clin Cancer Res. 2002 Mar;8(3):718-28
pubmed: 11895901
J Neurooncol. 2012 Mar;107(1):133-8
pubmed: 21984064
N Engl J Med. 1996 Jan 18;334(3):168-75
pubmed: 8531974
Br J Cancer. 2017 Mar 28;116(7):874-883
pubmed: 28222071
Neuro Oncol. 2012 Feb;14(2):215-21
pubmed: 22090453
Br J Cancer. 2010 Nov 23;103(11):1680-91
pubmed: 21045833
Cell Death Differ. 2006 Mar;13(3):446-53
pubmed: 16167071
J Clin Pathol. 2016 Sep;69(9):767-71
pubmed: 26797410
J Clin Pathol. 2015 Nov;68(11):946-7
pubmed: 26139632
PLoS One. 2006 Dec 20;1:e98
pubmed: 17183730
Clin Cancer Res. 2015 Jun 15;21(12):2666-70
pubmed: 25802282
Clin Pharmacol Ther. 2010 Feb;87(2):166-74
pubmed: 20010556
Expert Rev Hematol. 2013 Aug;6(4):351-9
pubmed: 23991922
Clin Transl Oncol. 2016 Nov;18(11):1123-1130
pubmed: 26942921
Mol Pharmacol. 2004 Mar;65(3):520-7
pubmed: 14978230
Neuro Oncol. 2012 Jan;14(1):93-100
pubmed: 22028388
Ann Clin Lab Sci. 2005 Autumn;35(4):397-406
pubmed: 16254255
Cytometry A. 2005 Jul;66(1):52-61
pubmed: 15915507
Blood. 2005 Feb 1;105(3):959-67
pubmed: 15466934
Molecules. 2016 Oct 21;21(10):
pubmed: 27775667
Metabolites. 2016 Mar 02;6(1):
pubmed: 26950159
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Mol Cancer Ther. 2009 Nov;8(11):3075-87
pubmed: 19887547
Clin Cancer Res. 2006 Jul 1;12(13):3997-4003
pubmed: 16818698
Cancer Chemother Pharmacol. 2014 Mar;73(3):495-501
pubmed: 24435060
Crit Rev Oncol Hematol. 2011 Dec;80(3):369-79
pubmed: 21330149
Immunotherapy. 2016 Jun;8(6):705-19
pubmed: 27197539
Ann Oncol. 2016 Sep;27(9):1746-53
pubmed: 27358379
J Exp Clin Cancer Res. 2017 Dec 06;36(1):177
pubmed: 29212503
Prostate. 2007 Jul 1;67(10):1099-110
pubmed: 17477369
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005